Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30841348 | 1.00 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL21906129 | 0.79 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL30665391 | 0.79 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL21906037 | 0.79 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL1828420 | 0.79 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL19925549 | 0.79 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL29464847 | 0.79 | HSD17B10 (0.50) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL30990696 | 0.78 | ABL1 (0.49) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL400161 | 0.76 | POLB (0.70) | HSD17B10ABL1RIN1NPC1RAB9A | |
| SCHEMBL15970465 | 0.76 | MAOA (0.53) | HSD17B10ABL1RIN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521399-B2 | Compound as voltage-gated sodium channel inhibitor | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-4570788-A1 | COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITOR | Guangzhou Fermion Technology Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4472966-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4455130-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| EP-4385980-A1 | INDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023150201-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-116462662-A | Aromatic ring Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3873893-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113272293-A | 2-amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitors | 默沙东公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20200140411-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | HSD17B10 3164/4885ABL1 1674/4885RIN1 2804/4885 |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | HSD17B10 2558/4885ABL1 1313/4885RIN1 1908/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | HSD17B10 2558/4885ABL1 1313/4885RIN1 1908/4885 |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | HSD17B10 2558/4885ABL1 1313/4885RIN1 1908/4885 |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | HSD17B10 2558/4885ABL1 1313/4885RIN1 1908/4885 |
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | SCN8A, SCN10A, SCN7A | HSD17B10 2644/4885ABL1 1065/4885RIN1 1215/4885 |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | HSD17B10 2558/4885ABL1 1313/4885RIN1 1908/4885 |
| US-20200140411-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | HSD17B10 2558/4885ABL1 1313/4885RIN1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.